Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

c-LEcta GmbH. (2/8/18). "Press Release: c-LEcta Closes Exclusive Supply Agreement with Global Pharma Company".

Organisations Organisation c-LEcta GmbH
  Organisation 2 NN (NO NAME)
  Group OTHER
Products Product industrial enzyme
Person Person Struhalla, Marc (c-LEcta GmbH 201105 Managing Director)

As a result of several years of successful collaboration in the field of biocatalysis, c-LEcta and a global leading producer of generic APIs have now closed an exclusive long term supply agreement for an enzyme developed by c-LEcta.

In the course of the collaboration the project partner has conceptualized a novel synthesis route for a large volume generic API while c-LEcta has engineered one of its proprietary nitrilases being used therein. Now, that the enzymatic production process has been implemented and validated, the API is manufactured in commercial scale, whereas c-LEcta is in charge of the commercial scale production of the customized Nitrilase for the exclusive supply.

“We were delighted to execute this supply agreement together with the partner being an innovative global player in the generic API market”, Marc Struhalla, CEO of c-LEcta, says. “This collaboration further proves that biocatalysis is a very valuable tool for the synthesis of APIs and that enzymes developed and produced by c-LEcta enable cost-leadership in the highly competitive market of generic APIs.”

Record changed: 2019-01-18


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for c-LEcta GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top